Structure Therapeutics (NASDAQ:GPCR), Inc. (NASDAQ: GPCR) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel small‐molecule modulators of G protein‐coupled receptors (GPCRs). Founded as a spin‐out from Sosei Heptares in early 2022, the company leverages a proprietary structure‐guided drug design platform to address high‐value therapeutic targets across pain, central nervous system, metabolic and immuno‐inflammatory disorders. Structure Therapeutics seeks to advance orally bioavailable, non‐opioid therapies by combining deep expertise in structural biology, medicinal chemistry and target validation.
The company’s research and development activities center on its proprietary GPCR platform, which integrates high‐resolution crystallography, computational modeling and advanced chemistry libraries. This platform allows Structure Therapeutics to systematically engineer receptor binding, selectivity and signaling profiles, accelerating the progression from target identification to clinical candidate. Its lead program, a selective modulator for chronic pain, is currently in early clinical evaluation and exemplifies the company’s approach to address unmet needs without relying on traditional opioid mechanisms.
Structure Therapeutics operates research facilities in Cambridge, UK, and Cambridge, Massachusetts, reflecting its commitment to maintaining strong discovery operations on both sides of the Atlantic. The company has established strategic partnerships and research collaborations with academic centers and biopharmaceutical organizations to expand its pipeline across multiple therapeutic areas. These alliances enhance its ability to rapidly advance preclinical candidates toward human studies while leveraging external expertise in disease biology and clinical development.
Under the leadership of CEO Robert Icke, a veteran in GPCR drug discovery, Structure Therapeutics is guided by a management team with extensive experience in bringing small‐molecule therapeutics from concept to market. The company’s board and scientific advisory committees feature industry leaders in structural biology, pharmacology and translational medicine. Together, they aim to harness the untapped potential of GPCR targets and deliver innovative therapeutics that improve patient outcomes worldwide.
